The results showed that FAP+CAFs may impair the efficacy of anti-PD-1 therapy in gastric cancer mice, and that IL-31 blockade can partially restore treatment sensitivity, potentially by alleviating the immunosuppressive effects associated with FAP+CAFs [Figure 6A and B]. The gene discussed is IL31; the disease is gastric cancer.